Biogen annual revenue
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Biogen Revenue Growth & History (BIIB)
Biogen reported $9.89B in revenue for fiscal 2025, an increase of 2.22% from the previous fiscal year.
View full Biogen company overviewBiogen annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $9.89B | $214.7M | +2.22% |
| 2024 | 2024-12-31 | $9.68B | −$159.7M | −1.62% |
| 2023 | 2023-12-31 | $9.84B | −$337.8M | −3.32% |
| 2022 | 2022-12-31 | $10.17B | −$808.3M | −7.36% |
| 2021 | 2021-12-31 | $10.98B | −$2.46B | −18.32% |
| 2020 | 2020-12-31 | $13.44B | −$933.3M | −6.49% |
| 2019 | 2019-12-31 | $14.38B | $925.0M | +6.88% |
| 2018 | 2018-12-31 | $13.45B | $1.18B | +9.61% |
| 2017 | 2017-12-31 | $12.27B | $825.1M | +7.21% |
| 2016 | 2016-12-31 | $11.45B | $685.0M | +6.36% |
| 2015 | 2015-12-31 | $10.76B | $1.06B | +10.93% |
| 2014 | 2014-12-31 | $9.70B | $2.77B | +39.97% |
| 2013 | 2013-12-31 | $6.93B | $1.42B | +25.66% |
| 2012 | 2012-12-31 | $5.52B | $467.8M | +9.27% |
| 2011 | 2011-12-31 | $5.05B | $332.2M | +7.04% |
| 2010 | 2010-12-31 | $4.72B | $339.1M | +7.75% |
| 2009 | 2009-12-31 | $4.38B | $279.8M | +6.83% |
| 2008 | 2008-12-31 | $4.10B | $925.9M | +29.19% |
| 2007 | 2007-12-31 | $3.17B | — | — |
Biogen quarterly revenue
Q2.08
Q3.08
Q1.09
Q2.09
Q3.09
Q4.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $2.74B | $90.5M | +3.42% |
| Q1 2026 | 2026-03-31 | $2.48B | $46.8M | +1.93% |
| Q4 2025 | 2025-12-31 | $2.28B | −$175.3M | −7.14% |
| Q3 2025 | 2025-09-30 | $2.53B | $68.9M | +2.79% |
| Q2 2025 | 2025-06-30 | $2.65B | $180.6M | +7.33% |
| Q1 2025 | 2025-03-31 | $2.43B | $140.5M | +6.13% |
| Q4 2024 | 2024-12-31 | $2.45B | $68.4M | +2.87% |
| Q3 2024 | 2024-09-30 | $2.47B | −$64.5M | −2.55% |
| Q2 2024 | 2024-06-30 | $2.46B | $8.9M | +0.36% |
| Q1 2024 | 2024-03-31 | $2.29B | −$172.5M | −7.00% |
| Q4 2023 | 2023-12-31 | $2.39B | −$157.7M | −6.20% |
| Q3 2023 | 2023-09-30 | $2.53B | $21.8M | +0.87% |
| Q2 2023 | 2023-06-30 | $2.46B | −$133.1M | −5.14% |
| Q1 2023 | 2023-03-31 | $2.46B | −$68.8M | −2.72% |
| Q4 2022 | 2022-12-31 | $2.54B | −$189.8M | −6.94% |
| Q3 2022 | 2022-09-30 | $2.51B | −$270.4M | −9.73% |
| Q2 2022 | 2022-06-30 | $2.59B | −$185.9M | −6.70% |
| Q1 2022 | 2022-03-31 | $2.53B | −$162.2M | −6.02% |
| Q4 2021 | 2021-12-31 | $2.73B | −$118.8M | −4.16% |
| Q3 2021 | 2021-09-30 | $2.78B | −$597.2M | −17.69% |
| Q2 2021 | 2021-06-30 | $2.77B | −$906.6M | −24.63% |
| Q1 2021 | 2021-03-31 | $2.69B | −$840.3M | −23.78% |
| Q4 2020 | 2020-12-31 | $2.85B | −$818.7M | −22.30% |
| Q3 2020 | 2020-09-30 | $3.38B | −$224.0M | −6.22% |
| Q2 2020 | 2020-06-30 | $3.68B | $64.9M | +1.79% |
| Q1 2020 | 2020-03-31 | $3.53B | $44.5M | +1.28% |
| Q4 2019 | 2019-12-31 | $3.67B | $145.0M | +4.11% |
| Q3 2019 | 2019-09-30 | $3.60B | $161.1M | +4.68% |
| Q2 2019 | 2019-06-30 | $3.62B | $260.2M | +7.75% |
| Q1 2019 | 2019-03-31 | $3.49B | $358.7M | +11.46% |
| Q4 2018 | 2018-12-31 | $3.53B | $219.3M | +6.63% |
| Q3 2018 | 2018-09-30 | $3.44B | $361.2M | +11.74% |
| Q2 2018 | 2018-06-30 | $3.36B | $278.1M | +9.03% |
| Q1 2018 | 2018-03-31 | $3.13B | $320.4M | +11.40% |
| Q4 2017 | 2017-12-31 | $3.31B | $435.0M | +15.15% |
| Q3 2017 | 2017-09-30 | $3.08B | $122.0M | +4.13% |
| Q2 2017 | 2017-06-30 | $3.08B | $184.2M | +6.36% |
| Q1 2017 | 2017-03-31 | $2.81B | $83.9M | +3.08% |
| Q4 2016 | 2016-12-31 | $2.87B | $32.7M | +1.15% |
| Q3 2016 | 2016-09-30 | $2.96B | $177.9M | +6.40% |
| Q2 2016 | 2016-06-30 | $2.89B | $302.6M | +11.68% |
| Q1 2016 | 2016-03-31 | $2.73B | $171.8M | +6.72% |
| Q4 2015 | 2015-12-31 | $2.84B | $198.6M | +7.52% |
| Q3 2015 | 2015-09-30 | $2.78B | $266.5M | +10.61% |
| Q2 2015 | 2015-06-30 | $2.59B | $170.1M | +7.02% |
| Q1 2015 | 2015-03-31 | $2.56B | $425.2M | +19.96% |
| Q4 2014 | 2014-12-31 | $2.64B | $674.8M | +34.33% |
| Q3 2014 | 2014-09-30 | $2.51B | $683.6M | +37.40% |
| Q2 2014 | 2014-06-30 | $2.42B | $698.0M | +40.50% |
| Q1 2014 | 2014-03-31 | $2.13B | $714.7M | +50.51% |
| Q4 2013 | 2013-12-31 | $1.97B | $548.0M | +38.65% |
| Q3 2013 | 2013-09-30 | $1.83B | $442.3M | +31.92% |
| Q2 2013 | 2013-06-30 | $1.72B | $302.5M | +21.29% |
| Q1 2013 | 2013-03-31 | $1.42B | $123.1M | +9.53% |
| Q4 2012 | 2012-12-31 | $1.42B | $91.2M | +6.87% |
| Q3 2012 | 2012-09-30 | $1.39B | $75.6M | +5.77% |
| Q2 2012 | 2012-06-30 | $1.42B | $212.4M | +17.57% |
| Q1 2012 | 2012-03-31 | $1.29B | $88.7M | +7.37% |
| Q4 2011 | 2011-12-31 | $1.33B | $107.7M | +8.84% |
| Q3 2011 | 2011-09-30 | $1.31B | $134.1M | +11.41% |
| Q2 2011 | 2011-06-30 | $1.21B | −$4.1M | −0.34% |
| Q1 2011 | 2011-03-31 | $1.20B | $94.4M | +8.51% |
| Q4 2010 | 2010-12-31 | $1.22B | $92.0M | +8.16% |
| Q3 2010 | 2010-09-30 | $1.18B | $55.3M | +4.94% |
| Q2 2010 | 2010-06-30 | $1.21B | $119.4M | +10.92% |
| Q1 2010 | 2010-03-31 | $1.11B | $72.4M | +6.99% |
| Q4 2009 | 2009-12-31 | $1.13B | — | — |
| Q3 2009 | 2009-09-30 | $1.12B | $27.5M | +2.52% |
| Q2 2009 | 2009-06-30 | $1.09B | $99.9M | +10.05% |
| Q1 2009 | 2009-03-31 | $1.04B | — | — |
| Q3 2008 | 2008-09-30 | $1.09B | — | — |
| Q2 2008 | 2008-06-30 | $993.4M | — | — |
Biogen revenue growth trends
Over the last five reported fiscal years, revenue declined from $13.44B to $9.89B, a compound annual decline of 5.96%. Biogen's latest reported quarter, Q2 2026, generated $2.74B in revenue, an increase of 3.42% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Biogen source filings ↗Community posts
Biogen and Eisai win Japanese approval for Leqembi injection pen
Biogen ($BIIB) and Eisai received Japanese approval for Leqembi Pen, a subcutaneous formulation of their treatment for early Alzheimer’s disease. The regimen uses two pens totaling 500 milligrams once weekly, offering an alternative to intr ...
